1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hyperphosphatemia In Chronic Kidney Disease - Drugs In Development, 2022, provides an overview of the Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Hyperphosphatemia, that is, abnormally high serum phosphate levels, can result from increased phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. This condition is most commonly seen in patients with chronic kidney disease. Signs and symptoms include fatigue, nausea, sleep disturbances, shortness of breath, bone and joint pain, pruritus and rash. Treatment includes phosphate binders and diuretics.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Hyperphosphatemia In Chronic Kidney Disease - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperphosphatemia In Chronic Kidney Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Preclinical and Discovery stages are 1, 3, 3, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders).
- The pipeline guide reviews pipeline therapeutics for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hyperphosphatemia In Chronic Kidney Disease (Nutritional Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Hyperphosphatemia In Chronic Kidney Disease - Overview
- Hyperphosphatemia In Chronic Kidney Disease - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Hyperphosphatemia In Chronic Kidney Disease - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Hyperphosphatemia In Chronic Kidney Disease - Companies Involved in Therapeutics Development
- Ardelyx Inc
- China Nuokang Bio-Pharmaceutical Inc
- Citragen Pharmaceuticals Inc
- OPKO Health Inc
- Panion & Bf Biotech Inc
- Shield Therapeutics Plc
- Unicycive Therapeutics Inc
- Vidasym Inc
- Vifor Pharma Ltd
- Hyperphosphatemia In Chronic Kidney Disease - Drug Profiles
- CGN-002 - Drug Profile
- Product Description
- Mechanism Of Action
- fermagate - Drug Profile
- Product Description
- Mechanism Of Action
- ferric citrate - Drug Profile
- Product Description
- Mechanism Of Action
- lanthanum dioxycarbonate - Drug Profile
- Product Description
- Mechanism Of Action
- lanthanum polystyrene sulfonate - Drug Profile
- Product Description
- Mechanism Of Action
- PT-20 - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecule for Hyperphosphatemia - Drug Profile
- Product Description
- Mechanism Of Action
- succharated ferric oxide - Drug Profile
- Product Description
- Mechanism Of Action
- tenapanor hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- VS-501 - Drug Profile
- Product Description
- Mechanism Of Action
- Hyperphosphatemia In Chronic Kidney Disease - Dormant Projects
- Hyperphosphatemia In Chronic Kidney Disease - Discontinued Products
- Hyperphosphatemia In Chronic Kidney Disease - Product Development Milestones
- Featured News & Press Releases
- Nov 10, 2022: Unicycive completes enrollment of pivotal bioequivalence study for RENAZORB (lanthanum dioxycarbonate), an investigational treatment for hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis
- Nov 06, 2022: Unicycive Therapeutics announces abstract on Renazorb selected for presentation at American Society of Nephrology’s Kidney Week 2022
- Feb 02, 2022: Unicycive announces Renazorb pre-clinical and clinical data selected for presentation at National Kidney Foundation Spring Clinical Meeting
- Nov 29, 2021: Unicycive Therapeutics receives confirmatory guidance on renazorb regulatory pathway
- Dec 09, 2020: Akebiashares program: current approaches for managing hyperphosphatemia and caring for patients via telehealth
- Jan 28, 2019: Velphoro doubles percentage of patients reaching target serum phosphorous levels in new study published in Journal of Renal Nutrition
- Jan 06, 2017: Shield Therapeutics Provides Update on PT20
- Oct 14, 2016: Keryx Biopharmaceuticals Announces Presentations of Data at the American Society of Nephrology Kidney Week 2016 Annual Meeting
- Sep 24, 2015: Keryx Receives European Approval for Fexeric (ferric citrate coordination complex) for the Treatment of Hyperphosphatemia in Adults With Chronic Kidney Disease
- May 07, 2015: Phosphate Therapeutics announces positive results in the PEACH pivotal study of its novel phosphate binder (PT20) for the treatment of hyperphosphataemia
- Mar 04, 2015: Keryx Biopharmaceuticals Announces Publication of Auryxia (ferric citrate) Analysis in Journal of the American Society of Nephrology
- Jan 09, 2015: Keryx Biopharmaceuticals Turns to Veeva Commercial Cloud to Support First FDA-Approved Product Launch
- Nov 17, 2014: Keryx Biopharmaceuticals Announces Trade Name Auryxia for Ferric Citrate
- Nov 15, 2014: Keryx Biopharmaceuticals Announces Results From Ferric Citrate Phase 3 Long-Term Safety Extension Study
- Oct 01, 2014: Keryx Biopharmaceuticals Announces Issuance of a New U.S. Patent for Ferric Citrate Covering Orally Administrable Forms
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Ardelyx Inc, 2022
- Hyperphosphatemia In Chronic Kidney Disease - Pipeline by China Nuokang Bio-Pharmaceutical Inc, 2022
- Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Citragen Pharmaceuticals Inc, 2022
- Hyperphosphatemia In Chronic Kidney Disease - Pipeline by OPKO Health Inc, 2022
- Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Panion & Bf Biotech Inc, 2022
- Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Shield Therapeutics Plc, 2022
- Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Unicycive Therapeutics Inc, 2022
- Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Vidasym Inc, 2022
- Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Vifor Pharma Ltd, 2022
- Hyperphosphatemia In Chronic Kidney Disease - Dormant Projects, 2022
- Hyperphosphatemia In Chronic Kidney Disease - Discontinued Products, 2022
- Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Ardelyx Inc
- China Nuokang Bio-Pharmaceutical Inc
- Citragen Pharmaceuticals Inc
- OPKO Health Inc
- Panion & Bf Biotech Inc
- Shield Therapeutics Plc
- Unicycive Therapeutics Inc
- Vidasym Inc
- Vifor Pharma Ltd
